What is HC Wainwright’s Forecast for CGEM Q1 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Cullinan Therapeutics in a report issued on Wednesday, January 29th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.80) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q2 2025 earnings at ($0.84) EPS and Q3 2025 earnings at ($0.90) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.09.

Separately, UBS Group initiated coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $30.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $32.50.

Cullinan Therapeutics Stock Performance

Shares of NASDAQ CGEM opened at $10.56 on Friday. The company’s 50 day moving average price is $11.70 and its 200-day moving average price is $15.19. Cullinan Therapeutics has a 52-week low of $9.50 and a 52-week high of $30.19. The company has a market capitalization of $614.91 million, a P/E ratio of -3.72 and a beta of -0.14.

Insider Transactions at Cullinan Therapeutics

In related news, CEO Nadim Ahmed sold 8,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total transaction of $99,708.00. Following the transaction, the chief executive officer now directly owns 263,150 shares of the company’s stock, valued at approximately $3,123,590.50. This represents a 3.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jennifer Michaelson sold 3,489 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.52, for a total value of $43,682.28. Following the completion of the sale, the insider now directly owns 104,453 shares of the company’s stock, valued at $1,307,751.56. This trade represents a 3.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,582 shares of company stock valued at $372,097 in the last quarter. 6.07% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of institutional investors have recently modified their holdings of CGEM. Squarepoint Ops LLC bought a new stake in Cullinan Therapeutics during the 2nd quarter valued at $186,000. The Manufacturers Life Insurance Company lifted its stake in shares of Cullinan Therapeutics by 40.7% in the second quarter. The Manufacturers Life Insurance Company now owns 15,175 shares of the company’s stock valued at $265,000 after buying an additional 4,393 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Cullinan Therapeutics by 18.3% during the third quarter. Assenagon Asset Management S.A. now owns 135,036 shares of the company’s stock valued at $2,261,000 after buying an additional 20,841 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Cullinan Therapeutics by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company’s stock worth $187,000 after acquiring an additional 4,380 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in shares of Cullinan Therapeutics by 22.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 21,362 shares of the company’s stock worth $358,000 after acquiring an additional 3,881 shares during the last quarter. 86.31% of the stock is owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.